Edited by experts from one of the world’s largest leukemia centers, this book provides information on the biology of the variety of leukemic disorders, up-to-date diagnostic testing and many new developments in therapy. Chapters covering new treatments present an outlook for the future and explain the rationale for ongoing clinical trials.

Topics include:

• Targeted therapy, e.g. tyrosine kinase inhibitors (Flt3, Aurora kinase inhibitors, kit inhibitors, BCR-ABL inhibitors)
• Ras inhibitors
• Epigenetic therapy (hypomethylaters and histone deacetylase inhibitors)
• Lenalidomide analogs
• New chemotherapy drugs, e.g. clofarabine, cloretazine, sapacitabine, forodesine
• Combinations of chemotherapy with kinase inhibitors (e.g. ALL induction protocols in combination with dasatinib or imatinib)
• New monoclonal antibodies (lumiliximab, humaxCD20, anti-CD40)
• Thrombopoietic agents

Leukemias: Principles and Practice of Therapy

• Includes practical information to guide you in challenging situations, such as treatment of elderly patients, pregnancy, relapsed and refractory disease
• Incorporates chapters on supportive care and pharmacologic information about the most frequently used drugs in this area